Insmed | INSM - Ativo Circulante





Ativo Circulante Alterar Data
BioMarin Pharmaceutical USD 3.95B 98.95M 2025-12
Cytokinetics USD 916.97M 60.37M 2025-12
DBV Technologies USD 88.88M 32.36M 2025-09
Gilead Sciences USD 19.89B 1.05B 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Insmed USD 1.79B 137.6M 2025-12
Novartis USD 28.2B 2.26B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Vertex Pharmaceuticals USD 11.2B 631.4M 2025-12